Brokerages predict that Clementia Pharmaceuticals Inc (NASDAQ:CMTA) will post ($0.41) earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Clementia Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.46) and the highest is ($0.32). Clementia Pharmaceuticals posted earnings of ($9.54) per share during the same quarter last year, which indicates a positive year-over-year growth rate of 95.7%. The company is scheduled to issue its next quarterly earnings report on Thursday, August 9th.
According to Zacks, analysts expect that Clementia Pharmaceuticals will report full-year earnings of ($1.77) per share for the current fiscal year, with EPS estimates ranging from ($2.00) to ($1.35). For the next fiscal year, analysts forecast that the company will post earnings of ($1.79) per share, with EPS estimates ranging from ($2.05) to ($1.27). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research firms that follow Clementia Pharmaceuticals.
Clementia Pharmaceuticals (NASDAQ:CMTA) last released its earnings results on Wednesday, May 9th. The company reported ($0.42) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.33) by ($0.09).
Several analysts have commented on CMTA shares. Zacks Investment Research cut shares of Clementia Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, May 14th. B. Riley started coverage on shares of Clementia Pharmaceuticals in a research note on Wednesday, March 28th. They issued a “buy” rating and a $25.00 target price for the company. Finally, ValuEngine raised shares of Clementia Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, May 2nd. One research analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $26.60.
CMTA stock traded down $0.10 during midday trading on Friday, hitting $14.00. The stock had a trading volume of 87,008 shares, compared to its average volume of 77,560. The stock has a market capitalization of $444.05 million and a P/E ratio of -1.77. Clementia Pharmaceuticals has a 12-month low of $11.72 and a 12-month high of $20.15.
Several hedge funds and other institutional investors have recently made changes to their positions in the company. Victory Capital Management Inc. grew its stake in shares of Clementia Pharmaceuticals by 12.7% during the 4th quarter. Victory Capital Management Inc. now owns 34,710 shares of the company’s stock valued at $659,000 after buying an additional 3,920 shares during the period. Alps Advisors Inc. lifted its holdings in shares of Clementia Pharmaceuticals by 21.0% during the 1st quarter. Alps Advisors Inc. now owns 40,943 shares of the company’s stock valued at $620,000 after acquiring an additional 7,116 shares in the last quarter. A.R.T. Advisors LLC acquired a new position in shares of Clementia Pharmaceuticals during the 1st quarter valued at $232,000. Birchview Capital LP lifted its holdings in shares of Clementia Pharmaceuticals by 72.7% during the 1st quarter. Birchview Capital LP now owns 38,000 shares of the company’s stock valued at $576,000 after acquiring an additional 16,000 shares in the last quarter. Finally, J. Goldman & Co LP acquired a new position in shares of Clementia Pharmaceuticals during the 4th quarter valued at $488,000. 71.24% of the stock is owned by institutional investors.
About Clementia Pharmaceuticals
Clementia Pharmaceuticals Inc, a clinical stage biopharmaceutical company, develops treatments for patients suffering from bone disorders and other diseases. Its lead product candidate is palovarotene, an oral small molecule for the treatment of fibrodysplasia ossificans progressive, multiple osteochondromas, dry eye disease, and other diseases is in the Phase 3 MOVE Trial.
Get a free copy of the Zacks research report on Clementia Pharmaceuticals (CMTA)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Clementia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clementia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.